GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Novartis puts a €2.7bn BET on MorphoSys
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
AbbVie sees a world according to GARP
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
Takeda thins the cell therapy pipeline
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
Roche perseveres with FAP
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
